RESUMO

A woman in her 60s with a history of adult-onset Still's disease (AOSD) in remission for 14 years received the ChAdOx1-S vaccine as a booster to her initial vaccination schedule (two doses of CoronaVac vaccine 6 months apart). Two weeks later, she consulted for symptoms suggestive of AOSD reactivation. This was confirmed during hospitalisation, where renal and cardiac involvement were also observed. Despite using high-dose corticosteroids, troponin T and N-terminal pro hormone B-type natriuretic peptide (NT-proBNP) were persistently elevated. Tocilizumab was used, with which the patient achieved complete remission of her symptoms and normalised her laboratory tests.

Assuntos

COVID-19 , ChAdOx1 nCoV-19/efeitos adversos , Doença de Still de Início Tardio , Corticosteroides , Vacinas contra COVID-19/efeitos adversos , Feminino , Humanos , Pessoa de Meia-Idade , Indução de Remissão